Persistence of antibody to Hepatitis A virus 20years after receipt of Hepatitis A vaccine in Alaska

被引:14
作者
Plumb, I. D. [1 ]
Bulkow, L. R. [1 ]
Bruce, M. G. [1 ]
Hennessy, T. W. [1 ]
Morris, J. [1 ]
Rudolph, K. [1 ]
Spradling, P. [2 ]
Snowball, M. [3 ]
McMahon, B. J. [3 ]
机构
[1] Ctr Dis Control & Prevent, Arctic Invest Program, Div Preparedness & Emerging Infect, Anchorage, AK USA
[2] Ctr Dis Control & Prevent, Epidemiol & Stat Branch, Div Viral Hepatitis, Atlanta, GA USA
[3] Alaska Native Tribal Hlth Consortium, Anchorage, AK USA
关键词
duration of protection; Hepatitis A; Hepatitis A vaccine; immunogenicity; infectious hepatitis; IMMUNOGENICITY; EPIDEMIOLOGY; CHILDREN;
D O I
10.1111/jvh.12676
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Hepatitis A vaccine is recommended for children 1year old to prevent hepatitis A virus (HAV) infection. However, the duration of vaccine-induced immunity is unknown. We evaluated a cohort of Alaska Native persons 20years after HAV vaccination. Children aged 3-6years had been previously randomized to receive three doses of HAV vaccine (360 ELISA units/dose) at: (i) 0,1,2months; (ii) 0,1,6months; and (iii) 0,1,12months. We measured anti-HAV antibody concentrations every 2-3years; described geometric mean concentrations (GMC) and the proportion with protective antibody (20 mIU mL(-1)) over time; and modelled the change in GMC using fractional polynomial regression. Of the 144 participants, after 20years 52 (36.1%) were available for the follow-up (17, 18, 17 children in Groups A, B and C, respectively). Overall, 46 (88.5%) of 52 available participants had anti-HAV antibody concentrations 20 mIU mL(-1), and overall GMC was 107 mIU mL(-1). Although GMC levels were lower in Group A (60; CI 34-104) than in Group B (110; CI 68-177) or Group C (184; CI 98-345) (B vs C: P=.168; A vs B/C: P=.011), there was no difference between groups after adjusting for peak antibody levels post-vaccination (P=.579). Models predicted geometric mean concentrations of 124 mIU mL(-1) after 25years, and 106 mIU mL(-1) after 30years. HAV vaccine provides protective antibody levels 20years after childhood vaccination. Lower antibody levels in Group A may be explained by a lower initial peak response. Our results suggest a booster vaccine dose is unnecessary for at least 25-30years.
引用
收藏
页码:608 / 612
页数:5
相关论文
共 15 条
  • [1] WHO position paper on hepatitis A vaccines: June 2012-Recommendations
    不详
    [J]. VACCINE, 2013, 31 (02) : 285 - 286
  • [2] Long-term immunogenicity of inactivated hepatitis A vaccine: Follow-up at 15 years
    Byrd, Kathy K.
    Bruden, Dana L.
    Bruce, Michael G.
    Bulkow, Lisa R.
    Zanis, Carolyn L.
    Snowball, Mary M.
    Homan, Chriss E.
    Hennessy, Thomas W.
    Williams, James L.
    Dunaway, Eitel
    Chaves, Sandra S.
    McMahon, Brian J.
    [J]. JOURNAL OF PEDIATRIC INFECTIOUS DISEASES, 2010, 5 (04) : 321 - 326
  • [3] Fiore Anthony E., 2006, Morbidity and Mortality Weekly Report, V55, P1
  • [4] Hammitt Laura L, 2008, J Infect Dis, V198, P1776, DOI 10.1086/593335
  • [5] Hepatitis A Epidemiology Goes Global
    Holmberg, Scott D.
    [J]. CLINICAL INFECTIOUS DISEASES, 2012, 54 (06) : 782 - 783
  • [6] The Evolving Epidemiology of Hepatitis A in the United States
    Klevens, R. Monina
    Miller, Jeremy T.
    Iqbal, Kashif
    Thomas, Ann
    Rizzo, Elena M.
    Hanson, Heather
    Sweet, Kristin
    Phan, Quyen
    Cronquist, Alicia
    Khudyakov, Yury
    Xia, Guo-liang
    Spradling, Philip
    [J]. ARCHIVES OF INTERNAL MEDICINE, 2010, 170 (20) : 1811 - 1818
  • [7] Seroprevalence of Hepatitis A Virus Antibodies in the US: Results from the National Health and Nutrition Examination Survey
    Klevens, R. Monina
    Kruszon-Moran, Deanna
    Wasley, Annemarie
    Gallagher, Kathleen
    McQuillan, Geraldine M.
    Kuhnert, Wendi
    Teshale, Eyasu H.
    Drobeniuc, Jan
    Bell, Beth P.
    [J]. PUBLIC HEALTH REPORTS, 2011, 126 (04) : 522 - 532
  • [8] SERUM NEUTRALIZING ANTIBODY-RESPONSE TO HEPATITIS-A VIRUS
    LEMON, SM
    BINN, LN
    [J]. JOURNAL OF INFECTIOUS DISEASES, 1983, 148 (06) : 1033 - 1039
  • [9] IMMUNOGENICITY OF AN INACTIVATED HEPATITIS-A VACCINE IN ALASKA NATIVE CHILDREN AND NATIVE AND NONNATIVE ADULTS
    MCMAHON, BJ
    WILLIAMS, J
    BULKOW, L
    SNOWBALL, M
    WAINWRIGHT, R
    KENNEDY, M
    KRAUSE, D
    [J]. JOURNAL OF INFECTIOUS DISEASES, 1995, 171 (03) : 676 - 679
  • [10] Long-term protective effects of hepatitis A vaccines. A systematic review
    Ott, Joerdis Jennifer
    Irving, Greg
    Wiersma, Steven Todd
    [J]. VACCINE, 2012, 31 (01) : 3 - 11